Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 48.4%

Biodesix, Inc. (NASDAQ:BDSX) was the recipient of a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 249,443 shares, a decrease of 48.4% from the January 15th total of 483,591 shares. Based on an average daily trading volume, of 419,332 shares, the days-to-cover ratio is presently 0.6 days. Approximately 4.5% of the shares of the company are short sold. Approximately 4.5% of the shares of the company are short sold. Based on an average daily trading volume, of 419,332 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Ratings Changes

BDSX has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Biodesix Stock Performance

NASDAQ:BDSX opened at $10.35 on Thursday. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The company has a fifty day moving average of $8.34 and a two-hundred day moving average of $7.96. The stock has a market capitalization of $82.34 million, a PE ratio of -1.86 and a beta of 0.67. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $20.40.

More Biodesix News

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Significant month‑end short interest drop (Jan. 30) — short interest fell about 48% to ~249k shares (~4.5% of float), reducing immediate short‑selling pressure and days‑to‑cover; this is supportive if the trend holds.
• Positive Sentiment: Some institutional buying reported in recent quarters (e.g., Aberdeen added shares in Q4), indicating selective investor interest from funds alongside other portfolio moves.
• Neutral Sentiment: Scheduled earnings and investor call are a near‑term catalyst — Biodesix will report Q4 and full‑year 2025 results after the close on Feb. 26 and host a 4:30 PM ET webcast; the event could swing the stock depending on results and guidance. Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
• Neutral Sentiment: Recent short‑interest prints for Feb. 10–11 show “0 shares” (likely a reporting/data anomaly). Treat those entries cautiously until exchanges/data vendors correct them; they create short‑term ambiguity in the market picture.
• Negative Sentiment: CEO Scott Hutton sold 3,559 shares (~$10.08 avg), reducing his stake ~7.3% — multiple executive sales can be a negative sentiment signal for investors. Insider Selling: Biodesix CEO Sells 3,559 Shares
• Negative Sentiment: CFO Robin Harper Cowie sold 941 shares at ~$10.08 (SEC filing). Executive selling by multiple officers (CFO, CAO, CCO, CDO) on the same date amplifies negative market perception. CFO Form 4
• Negative Sentiment: Other insiders sold on Feb. 10: Gary Pestano (540 sh), Kieran O’Kane (584 sh), Chris Vazquez (101 sh) — the cluster of small/medium insider sales likely contributes to intraday weakness. (See SEC filings for details.) Insider Sales SEC Filings

Insider Activity

In related news, CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total transaction of $35,874.72. Following the sale, the chief executive officer directly owned 45,413 shares of the company’s stock, valued at $457,763.04. This trade represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack W. Schuler purchased 20,000 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was bought at an average cost of $11.80 per share, with a total value of $236,000.00. Following the completion of the acquisition, the director directly owned 1,563,210 shares of the company’s stock, valued at $18,445,878. This trade represents a 1.30% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 182,465 shares of company stock worth $2,084,616 and have sold 7,672 shares worth $73,576. 30.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Biodesix

Several institutional investors have recently bought and sold shares of BDSX. XTX Topco Ltd increased its stake in Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Biodesix during the third quarter worth approximately $113,000. Oracle Investment Management Inc. acquired a new position in Biodesix in the 3rd quarter valued at $113,000. Geode Capital Management LLC raised its stake in Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after purchasing an additional 2,235 shares during the last quarter. Finally, Monashee Investment Management LLC lifted its holdings in Biodesix by 12.3% in the 4th quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock valued at $764,000 after purchasing an additional 12,348 shares in the last quarter. 20.96% of the stock is currently owned by institutional investors and hedge funds.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.